Archive: 19/05/2015

DUR-928 compound continues phase 1 clinical trials

A therapeutic compound developed at Virginia Commonwealth University, which may have broad applicability in acute organ injuries and in several metabolic diseases such as nonalcoholic fatty liver disease and nonalcoholic ...

page 10 from 11